CPHI Online is the largest global marketplace in the pharma ingredients industry
Discover the CPHI North America Learning Labs: Part One
Explore the series of Learning Labs at CPHI North America across several product innovation categories in which thought leaders at our exhibitors showcase their extensive expertise in all areas of the pharma supply chain, offering industry insights across drug manufacturing, outsourcing, pharma ingredients, drug delivery and packaging.
Within this summary, we provide a taster of what some of them have to offer. All this knowledge is available to you at your desktop – all you need to do is register for the event here.
You can access Part Two here.
Unlocking the Power and Versatility of Plant-Based Softgels
In this session, Carlos Perez, Commercial Director, Unigel technology, Procaps and Carolina Quintero, Director of New Pharmaceutical Technologies, Procaps run the rule over vegetarian soft capsules which constitute 10-15% of the total soft capsule market amid a rise in popularity of plant-based diets.
“There is a big expectation regarding more competitive offers for these materials, the optimisation of processing technology as well as the expansion of the pharmaceutical market,” Perez says. “The plant-based trend is here to stay.”
He adds that according to Mintel, plant-based diets have been growing in popularity, reflecting consumer desires to act more sustainably and eat more healthfully.
“Also, the pandemic has given consumers more reasons to avoid animal-based foods, which will lead to more growth for the plant-based category,” he says.
Lonza Quakertown - Micronization & Particle Size Control
Lonza Quakertown provides expertise in particle size reduction and classification servicing the cGMP pharmaceutical marketplace. This presentation by Michael Bauer, Site Head, Lonza Quakertown, Lonza provides a description of the site and its sister site at Monteggio, Switzerland and an overview of capabilities specific to micronization and classification while highlighting the value of particle size reduction and control.
“In terms of micronization, we’re able to support a client base which ranges from the virtual pharma smaller companies all the way up to big pharma partners,” Bauer says. “We’re able to combine our expertise with hundreds of different molecules and a wide array of equipment. We basically have the tools and knowhow to handle a wide array of product challenges.”
Lonza Tampa - Expansions in HPAPI for Oral Solid and Inhalation Technology
Lonza’s facilities in Tampa, Florida are an integral component of the company’s design, development and manufacturing network for drug substances and specialized drug products. Working collaboratively with customers, the Tampa team designs, develops and manufactures oral solid and inhalation drug products.
In this session, Jeff Williamson, Director, Product Development, Lonza explains how the Tampa site provides a full range of services, starting from initial stages of product development including pre-formulation, formulation & process design, and analytical method development. These services extend into early phase clinical, late phase clinical, and commercial scale production including packaging and distribution worldwide.
“Lonza employs a Harro Höfliger encapsulator system for larger scale production in supporting both oral solid and dry powder for inhalation product development,” he says. “These systems have high speed, large volume capabilities and provide an efficient pathway to commercialising API and capsule formulations.”
Proactive Planning for Supply Chain Risk Mitigation
In this learning lab, Scott Rizzo, Senior Vice President and General Manager, Recro focuses on a topic that has become very much in vogue in recent months – management of supply chain disruption. Amid the COVID-19 pandemic, many life sciences companies are now putting in place strategies to address secondary suppliers and to mitigate supply chain interruptions.
Rizzo runs through the most common types of disruption in the pharma sector, highlights the preventative strategies that can be employed to tackle them and addresses some of the misconceptions about secondary sourcing.
“When you think about all the items that go into your product, there are going to be some that are more critical than others – what are the longest lead times and the gaps that you have,” Rizzo says. “Develop a plan and really put the work into it; take everything from an internal and external standpoint and work your way back.”
Packaging & Drug Delivery
Understanding USP 661.2 and Strategies for Compliance
The focus of this session led by Jason Eckel, Vice President, Sales - Healthcare, Transcendia is USP 661 regulations that impact pharmaceutical packaging systems, including those used during pharmaceutical manufacturing such as chutes, tubes, bags and binliners for non-liquids.
“We have seen that many pharmaceutical companies focus on the final packaging and the regulations that apply there and fail to assess their supply chain for the risk of non-compliant packaging systems in the main manufacturing environment especially when APIs and excipients are being outsourced and those packaging decisions are left to their outsourcing partners,” he says. “USP has been clear that the new regulations in 661.2 apply to all products that come in contact during the manufacturing, distribution and administration of ingredients and finished pharmaceuticals.”
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases.
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO:
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity.
Enzyme replacement therapeutic Xenpozyme has received US FDA approval with an orphan drug designation to treat symptoms of Acid Sphingomyelinase Deficiency, a rare genetic disease.
The pharmaceutical companies behind the leading COVID-19 vaccines are in a legal dispute over intellectual property rights surrounding the mRNA vaccines that were released after emergency use authorization in December 2020.
With the rapid development and manufacturing of new drugs and therapeutics being pushed through the pipeline, excipient manufacturers are navigating a challenging landscape to meet the demand for new and novel excipients.
News Thermo Fisher Scientific expands viral vector manufacturing capabilities with Plainville facilityThermo Fisher Scientific’s new Plainville, MA viral vector manufacturing facility has opened, expanding the company's cell and gene therapy capabilities with advancing bioproduction and analytical instrumentation technologies.
Catalent Inc. is set to acquire Metrics Contract Services in a USD $475 million bid to expand its high-potent capacities and oral development and manufacturing capabilities by the end of 2022
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance